What is AB Science?
Founded in 2001, AB Science is dedicated to the research, development, and commercialization of innovative protein kinase inhibitors. The company's proprietary portfolio includes masitinib, a lead compound that has received approval in veterinary medicine and is undergoing development for various human medical applications. AB Science targets critical therapeutic areas such as oncology, neurological diseases, inflammatory diseases, and viral diseases, aiming to address significant gaps in current treatment options. The company's public trading on Euronext Paris and its operational presence across Europe and North America highlight its established position in the biopharmaceutical sector.
How much funding has AB Science raised?
AB Science has raised a total of $42.9M across 5 funding rounds:
Share Placement
$18.3M
Debt
$7.2M
Debt
$8.5M
Stock/Share Issuance
$2M
Stock/Share Issuance
$3.2M
Share Placement (2020): $18.3M with participation from Undisclosed
Debt (2021): $7.2M led by Societe Generale, Bpifrance, and Banque Populaire Group
Debt (2022): $8.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $2M, investors not publicly disclosed
Stock/Share Issuance (2025): $3.2M, investors not publicly disclosed
Key Investors in AB Science
Societe Generale
Société Générale is a French multinational financial services company providing a wide range of banking and insurance services. Its involvement suggests a strong financial backing for AB Science's growth initiatives.
Bpifrance
Bpifrance is a French public investment bank that finances companies at various stages of development, supporting innovation and international expansion. Their participation highlights a strategic alignment with national economic development goals.
Banque Populaire Group
Banque Populaire Group is a prominent French banking group, offering comprehensive financial services. Their investment signifies confidence in AB Science's market potential and financial stability.
What's next for AB Science?
The recent major enterprise-level funding indicates a significant scaling phase for AB Science. This capital infusion is expected to accelerate the clinical development pipeline, potentially leading to expanded regulatory approvals for masitinib and other pipeline candidates. The strategic investment will likely bolster research and development efforts, enhance manufacturing capabilities, and support broader market penetration. AB Science's focus on diseases with high unmet medical needs positions it for continued growth and impact within the global pharmaceutical landscape.
See full AB Science company page
